'Pk pd' presentation slideshows

Dose extrapolation from in vitro to in vivo and across species

Dose extrapolation from in vitro to in vivo and across species. Pierre-Louis Toutain Royal veterinary College London & project officer at the ENV of Toulouse. Wuhan University October 2017.

1.2k views • 105 slides

How to establish a dosage regimen for a sustainable use of antibiotics in veterinary medicine

How to establish a dosage regimen for a sustainable use of antibiotics in veterinary medicine. P.L. Toutain National Veterinary School ; Toulouse, France. The workshop. A general presentation by PLT Three questions to be discussed in subgroups animated by team leaders: Peter Lees:

1.05k views • 79 slides

Multiple Myeloma ASH 2013

Multiple Myeloma ASH 2013. Ashley Rosko MD Ashley.Rosko@osumc.edu . Check us out on www.OhioMyeloma.org www.cancer.osu.edu/go/myelomateam. 8 Take Homes Points: ASH 2013 Overview. Lay of the Land: therapeutics Newly Diagnosed MM Maintenance Supportive Care Relapsed/Refractory MM. 1.

704 views • 49 slides

Young Innovators 2011

545 views • 46 slides

SphingoGene, Inc. Delaware C-Corporation James S Norris PhD Board President and Interim CEO norrisjs@musc.edu

Small Molecule Platform Improving Radiation Treatment. SphingoGene, Inc. Delaware C-Corporation James S Norris PhD Board President and Interim CEO norrisjs@musc.edu. Objective. To obtain funding or partnerships in order to complete preclinical development of SPG105 for IND filing.

578 views • 42 slides

Jim Pickett, AFC/IRMA Los Angeles Biomedical Forum May 31, 2013

549 views • 41 slides

8th ISAP Symposium

8th ISAP Symposium. Can PK/PD be used in everyday clinical practice?. Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University of Milan, Milan, Italy. PK/PD results and evolution. }. }. Improvement of dose and intervals. Outcome resistance.

517 views • 35 slides

The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD

The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida. PHARMACOKINETICS what the body does to the drug PHARMACODYNAMICS what the drug does to the body. Pharmacokinetics conc. vs time. Pharmacodynamics conc. vs effect. 0.4. 1. Conc.

557 views • 34 slides

477 views • 33 slides

441 views • 33 slides

Regulatory and Scientific Issues of Biosimilars

Regulatory and Scientific Issues of Biosimilars . Duu-Gong Wu, Ph.D. Executive Director, PharmaNet Member, FDA Alumni Association DIA China, Beijing, China May 16-18, 2011. Disclosures.

1.01k views • 31 slides

Summary of Pediatric Clinical Trial Data : Fluticasone and Budesonide Pediatric Advisory Committee Meeting September 1

493 views • 26 slides

PK/PD Modeling of Therapeutic Effects of Erythropoietin

PK/PD Modeling of Therapeutic Effects of Erythropoietin. Wojciech Krzyzanski, PhD, MA Department of Pharmaceutical Sciences University at Buffalo. Semiparametric Bayesian Inference: Applications in Pharmacokinetics and Pharmacodynamics SAMSI, Research Triangle Park, July 14 2010.

469 views • 26 slides

WHICH PK-PD MEASURE FOR WHICH DRUG?

WHICH PK-PD MEASURE FOR WHICH DRUG?. The Life and Times of Dr. William A. Craig. Sujata M. Bhavnani, Pharm.D, MS Institute for Clinical Pharmacodynamics Ordway Research Institute Latham, New York. ROAD MAP Objectives.

432 views • 25 slides

Dosage Determination from Preclinical to Proof-of-Concept Trials, (Including Toxicology)

Dosage Determination from Preclinical to Proof-of-Concept Trials, (Including Toxicology). Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA. Choosing Doses for POC:. Preclinical and early studies that enable dose selection Reasons for drug failure in clinical phase 2-3

789 views • 23 slides

Follow-on or Biosimilar Biologic s Points to Consider Paul Kim Foley Hoag LLP Massachusetts Biotechnology Council Thurs

370 views • 17 slides

A Winning Strategy On Data Quality - Putting the Right Pieces Together

A Winning Strategy On Data Quality - Putting the Right Pieces Together. May 17th, 2011 | Beijing, China. Highlights. The quality control system on data management in clinical trials What are the challenges Building sustainable organizational capability of quality assurance.

345 views • 16 slides

The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit

234 views • 12 slides

Pharmacodynamics & Pharmacokinetics: PI and PIL considerations

Pharmacodynamics & Pharmacokinetics: PI and PIL considerations. Douglas W Oliver School of Pharmacy / Unit for Drug Research & Development. SAAPRA 16 November 2012. Presentation. Introduction: Drug Discovery Research Background: PK/PD Pharmacodynamics (CTD Modules 4&5) Pharmacokinetics

340 views • 4 slides

ABPI NaBDEN: Areas of interest for ITTP studentships

Cellular and molecular mechanisms that underpin organ toxicities, with special focus on CNS, the immune system, kidney, testicular, pulmonary, liver and cardiovascular toxicity

247 views • 1 slides